Axon vs. CrowdStrike—Flip a Coin, It’s Still Just Stock Picking

Two security stocks walk into a portfolio, and somehow people treat this like a philosophical dilemma. It’s not. It’s a valuation question, and most of you will get it wrong because you’ll fall in love with a story instead of reading a balance sheet.

Axon Enterprise sells Tasers and body cameras to law enforcement. CrowdStrike sells cloud cybersecurity through its Falcon platform. Both operate in mission-critical niches with genuine competitive moats—Axon’s hardware-and-evidence ecosystem locks in police departments the way changing your bank is annoying, and CrowdStrike’s endpoint security is entrenched across enterprise fleets. Fine. The business quality isn’t the debate.

The debate is price, and this is where everyone’s brain conveniently shuts off. Axon has traded at valuations that assume decades of flawless execution are already priced in. CrowdStrike, despite a genuine security breach in 2024 that grounded flights and hospitals, still commanded a rich multiple because the market decided endpoint security is worth perfection-level pricing. A company whose entire product is “nothing bad will happen” suffered a very public “bad thing happened,” and the stock barely flinched. That’s not conviction. That’s momentum dressed up as analysis.

Here’s the question nobody asking “which is a better buy” bothers to run: what growth is already baked into the price? If you pay 60-plus times earnings for anything, you need years of 25-30% growth just to justify today’s price, with zero margin for error. Both of these companies have been excellent. Excellent and cheap are different words. A great business at a stupid price is a bad investment—the same asset, just bought at the wrong number. Ask anyone who bought Cisco in 2000 how their wonderful business worked out. It took the index-twenty years to recover while an S&P 500 fund quietly doubled their money by doing nothing.

And that’s the real opportunity cost here. Every dollar you sink into a hyper-priced growth stock is a dollar not in a low-cost index fund compounding at market rates with a 0.03% expense ratio instead of the 1%+ you’ll pay some advisor to pick these names for you. Fees compound too—just in the wrong direction.

If you must own one of these, understand what you’re buying: not a security company, but a bet that the market’s enthusiasm persists for another decade. Both companies will probably be fine. Your returns depend far less on whether Axon or CrowdStrike executes than on whether you overpaid for the privilege of watching them do it.

The market doesn’t reward you for picking good companies. It rewards you for buying good companies at prices other people were too distracted to notice were bad.